Multiple myeloma: evolving genetic events and host interactions
The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
Multiple myeloma is a neoplasm of terminally differentiated B cells (plasma cells) in which chromosome translocations frequently place oncogenes under the control of immunoglobulin enhancers. Unlike most haematopoietic cancers, multiple myeloma often has complex chromosomal abnormalities that are reminiscent of epithelial tumours. What causes full-blown myeloma? And can our molecular understanding of this common haematological malignancy be used to develop effective preventive and treatment strategies?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [38]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“asp?DrugCode=1%2D11465&DrugName=THALIDOMIDE+ORAL&DrugType=1">thalidomide”
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510350091047 · Cited by 1,791
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas
Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S. K., Küppers, R., & Dalla-Favera, R. (2001) · Nature · doi:10.1038/35085588 · Cited by 1,032
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Superoxide dismutase as a target for the selective killing of cancer cells
Huang, P., Feng, L., Oldham, E. A., Keating, M. J., & Plunkett, W. (2000) · Nature · doi:10.1038/35030140 · Cited by 842
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M.-L., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
Mechanisms of chromosomal translocations in B cell lymphomas
Küppers, R., & Dalla-Favera, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204640 · Cited by 660
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Self-citationVacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
Chesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Self-citationDankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes
Romanov, S. R., Kozakiewicz, B. K., Holst, C. R., Stampfer, M. R., Haupt, L. M., & Tlsty, T. D. (2001) · Nature · doi:10.1038/35054579 · Cited by 560
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy, W. T., Richter, L., Frutiger, Y. M., & Grogan, T. M. (1999) · PubMed · Cited by 559
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Interleukin-6 in human multiple myeloma
Klein, B., Zhang, X., Lu, Z., & Bataille, R. (1995) · Blood · doi:10.1182/blood.v85.4.863.bloodjournal854863 · Cited by 520
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
Ayton, P. M., & Cleary, M. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204639 · Cited by 500
Chromosome translocations in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204641 · Cited by 478
Self-citationBiologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478
Synergistic Roles for Pim-1 and c-Myc in STAT3-Mediated Cell Cycle Progression and Antiapoptosis
Shirogane, T., Fukada, T., Muller, J. M. M., Shima, D. T., Hibi, M., & Hirano, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80145-4 · Cited by 426
Uchiyama, H., Barut, B., Mohrbacher, A., Chauhan, D., & Anderson, K. (1993) · Blood · doi:10.1182/blood.v82.12.3712.3712 · Cited by 418
Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M. (1998) · Blood · doi:10.1182/blood.v91.12.4457 · Cited by 401
Self-citationDewald, G., Kyle, R., Hicks, G., & Greipp, P. (1985) · Blood · doi:10.1182/blood.v66.2.380.380 · Cited by 401
Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M. (1998) · Blood · doi:10.1182/blood.v91.12.4457.412k48_4457_4463 · Cited by 400
Self-citationIL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., & Anderson, K. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2212 · Cited by 399
Hypodiploidy is a major prognostic factor in multiple myeloma
Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., & Fruchart, C. (2001) · Blood · doi:10.1182/blood.v98.7.2229 · Cited by 390
STAT3 Is Required for the gp130-mediated Full Activation of the c-myc Gene
Kiuchi, N., Nakajima, K., Ichiba, M., Fukada, T., Narimatsu, M., Mizuno, K., Hibi, M., & Hirano, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.1.63 · Cited by 385
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., & Kuehl, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13931 · Cited by 367
Self-citationShou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., Dewald, G., Kirsch, I. R., Bergsagel, P. L., & Kuehl, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.228 · Cited by 347
Self-citationHan, J.-H., Choi, S. J., Kurihara, N., Koide, M., Oba, Y., & Roodman, G. D. (2001) · Blood · doi:10.1182/blood.v97.11.3349 · Cited by 328
Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., et al. (2000) · Blood · doi:10.1182/blood.v95.6.1925 · Cited by 321
Stromal cells can contribute oncogenic signals
Tlsty, T. D. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0361 · Cited by 321
Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., et al. (2000) · Blood · doi:10.1182/blood.v95.12.4008 · Cited by 320
A critical role for telomeres in suppressing and facilitating carcinogenesis
Artandi, S. E., & DePinho, R. A. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00047-7 · Cited by 318
Prognostic value of bone marrow angiogenesis in multiple myeloma.
Rajkumar, S. V., Leong, T. L., Roche, P. C., Fonseca, R., Dispenzieri, A. A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Kyle, R. A., Gertz, M. A., et al. (2000) · PubMed · Cited by 315
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Intrinsic Constraint on Plasmablast Growth and Extrinsic Limits of Plasma Cell Survival
Sze, D. M.-Y., Toellner, K.-M., de Vinuesa, C. G., Taylor, D. R., & MacLennan, I. C. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.6.813 · Cited by 312
Biology of Osteoclast Activation in Cancer
Roodman, G. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3562 · Cited by 306
Plasma cells: finding new light at the end of B cell development
Calame, K. L. (2001) · Nature Immunology · doi:10.1038/ni1201-1103 · Cited by 306
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Self-citationRearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.-L., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v98.10.3082 · Cited by 289
Chesi, M., Bergsagel, P., Brents, L., Smith, C., Gerhard, D., & Kuehl, W. (1996) · Blood · doi:10.1182/blood.v88.2.674.bloodjournal882674 · Cited by 277
Self-citationWWOX, the FRA16D gene, behaves as a suppressor of tumor growth.
Bednarek, A. K., Keck-Waggoner, C. L., DANIEL, R. L., Laflin, K. J., Bergsagel, P. L., Kiguchi, K., Brenner, A., & Aldaz, C. M. (2001) · PubMed · Cited by 272
Self-citationTu, Y., Gardner, A. M., & Lichtenstein, A. K. (2000) · PubMed · Cited by 270
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995) · Blood · doi:10.1182/blood.v86.2.685.bloodjournal862685 · Cited by 269
Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes
Papavasiliou, F. N., & Schatz, D. G. (2000) · Nature · doi:10.1038/35041599 · Cited by 261
Yaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
Döhner, H., Stilgenbauer, S., Döhner, K., Bentz, M., & Lichter, P. (1999) · Journal of Molecular Medicine · doi:10.1007/s001090050350 · Cited by 249
Shaughnessy, J., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., Sawyer, J., Barlogie, B., Bergsagel, P. L., & Kuehl, M. (2001) · Blood · doi:10.1182/blood.v98.1.217 · Cited by 223
Self-citationSawyer, J. R., Tricot, G., Mattox, S., Jagannath, S., & Barlogie, B. (1998) · Blood · doi:10.1182/blood.v91.5.1732 · Cited by 217
Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N., Greipp, P., Kyle, R., Oken, M., & Van Ness, B. (1996) · Blood · doi:10.1182/blood.v88.7.2699.bloodjournal8872699 · Cited by 215
Michigami, T., Shimizu, N., Williams, P. J., Niewolna, M., Dallas, S. L., Mundy, G. R., & Yoneda, T. (2000) · Blood · doi:10.1182/blood.v96.5.1953 · Cited by 214
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy
Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E., & Maiolo, A. (1993) · Blood · doi:10.1182/blood.v81.1.128.128 · Cited by 199
Interleukin-6 is a growth factor for nonmalignant human plasmablasts
Jego, G., Bataille, R., & Pellat-Deceunynck, C. (2001) · Blood · doi:10.1182/blood.v97.6.1817 · Cited by 198
Avet‐Loiseau, H., Facon, T. T. F., Daviet, A., Godon, C., Rapp, M.-J., Harousseau, J., Grosbois, B., & Bataille, R. (1999) · PubMed · Cited by 194
Avet-Loiseau, H., Li, J.-Y., Morineau, N., Facon, T., Brigaudeau, C., Harousseau, J.-L., Grosbois, B., & Bataille, R. (1999) · Blood · doi:10.1182/blood.v94.8.2583.420a05_2583_2589 · Cited by 192
Drach, J. W., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C. A., Gsur, A., Jaeger, U., & Heinz, R. (1995) · PubMed · Cited by 192
Sezer, O., Jakob, C., Eucker, J., Niemoller, K., Gatz, F., Wernecke, K.-D., & Possinger, K. (2001) · European Journal of Haematology · doi:10.1034/j.1600-0609.2001.00348.x · Cited by 181
Bezieau, S., Devilder, M.-C., Avet-Loiseau, H., Mellerin, M.-P., Puthier, D., Pennarun, E., Rapp, M.-J., Harousseau, J.-L., Moisan, J.-P., & Bataille, R. (2001) · Human Mutation · doi:10.1002/humu.1177 · Cited by 180
Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
Georgii-Hemming, P., Wiklund, H., Ljunggren, O., & Nilsson, K. (1996) · Blood · doi:10.1182/blood.v88.6.2250.bloodjournal8862250 · Cited by 177
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
Shaughnessy, J., Tian, E., Sawyer, J., Bumm, K., Landes, R., Badros, A., Morris, C., Tricot, G., Epstein, J., & Barlogie, B. (2000) · Blood · doi:10.1182/blood.v96.4.1505 · Cited by 175
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth
Ge, N.-L., & Rudikoff, S. (2000) · Blood · doi:10.1182/blood.v96.8.2856 · Cited by 175
New insights into role of microenvironment in multiple myeloma
Tricot, G. J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)00019-2 · Cited by 174
Sawyer, J. R., Lukacs, J. L., Munshi, N., Desikan, K. R., Singhal, S., Mehta, J., Siegel, D., Shaughnessy, J., & Barlogie, B. (1998) · Blood · doi:10.1182/blood.v92.11.4269 · Cited by 172
Pérez-Simón, J. A., Garcı́a-Sanz, R., Tabernero, M. D., Almeida, J., González, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., Miguel, J. F. S., & Orfão, A. (1998) · Blood · doi:10.1182/blood.v91.9.3366 · Cited by 169
MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE
Kyle, R. A., & Rajkumar, S. V. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70120-9 · Cited by 167
Callander, N. S., & Roodman, G. D. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90020-4 · Cited by 166
Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G., & Stewart, A. K. (2000) · Blood · doi:10.1182/blood.v95.3.992.003k29_992_998 · Cited by 165
Self-citationThalidomide for previously untreated indolent or smoldering multiple myeloma
Rajkumar, S., Dispenzieri, A., Fonseca, R., Lacy, M., Geyer, S., Lust, J., Kyle, R., Greipp, P., Gertz, M., & Witzig, T. (2001) · Leukemia · doi:10.1038/sj.leu.2402183 · Cited by 164
Cohen, H. J., Crawford, J., Rao, M. K., Pieper, C. F., & Currie, M. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00080-1 · Cited by 162
The Proliferative Potential of Myeloma Plasma Cells Manifest in the SCID-hu Host
Yaccoby, S., & Epstein, J. (1999) · Blood · doi:10.1182/blood.v94.10.3576.422k01_3576_3582 · Cited by 159
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Urashima, M., Chen, B. P., Chen, S., Pinkus, G. S., Bronson, R. T., Dedera, D. A., Hoshi, Y., Teoh, G., Ogata, A., Treon, S. P., et al. (1997) · Blood · doi:10.1182/blood.v90.2.754 · Cited by 159
Lokhorst, H., Lamme, T., de Smet, M., Klein, S., de Weger, R., van Oers, R., & Bloem, A. (1994) · Blood · doi:10.1182/blood.v84.7.2269.2269 · Cited by 159
Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells
Puthier, D., Derenne, S., Barillé, S., Moreau, P., Harousseau, J., Bataille, R., & Amiot, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01705.x · Cited by 157
Vanderkerken, K., De Raeve, H., Goes, E., Van Meirvenne, S., Radl, J., Van Riet, I., Thielemans, K., & Van Camp, B. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.409 · Cited by 153
Ferlin, M., Noraz, N., Hertogh, C., Brochier, J., Taylor, N., & Klein, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02364.x · Cited by 153
Hayman, S. R., Bailey, R. J., Jalal, S. M., Ahmann, G. J., Dispenzieri, A. A., Gertz, M. A., Greipp, P. R., Kyle, R. A., Lacy, M. Q., Rajkumar, S. V., et al. (2001) · Blood · doi:10.1182/blood.v98.7.2266 · Cited by 150
Cigudosa, J. C., Rao, P. H., Calasanz, M. J., et al. (1998) · Blood · doi:10.1182/blood.v91.8.3007.3007_3007_3010 · Cited by 146
Prognostic value of cytogenetics in multiple myeloma
Seong, C., Delasalle, K. B., Hayes, K. J., Weber, D., Dimopoulos, M. A., Swantkowski, J., Huh, Y. O., Glassman, A. B., Champlin, R. E., & Alexanian, R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00657.x · Cited by 145
Human Cell Culture: Volume VI: Embryonic Stem Cells
Masters, J. R., Thomson, J. A., & Palsson, B. Ø. (2007) · Human cell culture · doi:10.1007/978-1-4020-5983-4 · Cited by 144
Fonseca, R., Oken, M., Harrington, D. P., Bailey, R., Wier, S. V., Henderson, K. J., Kay, N. E., Ness, B. V., Greipp, P., & Dewald, G. (2001) · Leukemia · doi:10.1038/sj.leu.2402125 · Cited by 140
Pilarski, L. M., Hipperson, G., Seeberger, K. L., et al. (2000) · Blood · doi:10.1182/blood.v95.3.1056.003k26_1056_1065 · Cited by 138
Dallas, S. L., Garrett, I. R., Oyajobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J., & Mundy, G. R. (1999) · Blood · doi:10.1182/blood.v93.5.1697 · Cited by 137
Small molecule modulators of cyclin-dependent kinases for cancer therapy
Senderowicz, A. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204085 · Cited by 132
A transcriptional repressor of c-myc
Kakkis, E., Riggs, K. J., Gillespie, W., & Calame, K. L. (1989) · Nature · doi:10.1038/339718a0 · Cited by 129
Loss of PTEN expression leading to high Akt activation in human multiple myelomas
Hyun, T., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J. S., & Li, W. (2000) · Blood · doi:10.1182/blood.v96.10.3560 · Cited by 127
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias
Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D., Boccadoro, M., & Pileri, A. (1993) · Blood · doi:10.1182/blood.v81.10.2708.2708 · Cited by 122
Common Modifications of Trimeric G Proteins and ras Protein: Involvement of Polyisoprenylation
Finegold, A. A., Schafer, W. R., Rine, J., Whiteway, M. S., & Tamanoi, F. (1990) · Science · doi:10.1126/science.1695391 · Cited by 120
A murine model of human myeloma bone disease
Garrett, I. R., Dallas, S. L., Radl, J., & Mundy, G. R. (1997) · Bone · doi:10.1016/s8756-3282(97)00056-2 · Cited by 118
Drexler, H. G., & Matsuo, Y. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00195-2 · Cited by 116
Current status of clinical trials of farnesyltransferase inhibitors
Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., & End, D. W. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00009 · Cited by 112
Hanamura, I., Iida, S., Akano, Y., Hayami, Y., Kato, M., Miura, K., Harada, S., Banno, S., Wakita, A., Kiyoi, H., et al. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01142.x · Cited by 112
Stromal abnormalities in neoplastic bone marrow diseases
Dührsen, U., & HOSSFELD, D. K. (1996) · Annals of Hematology · doi:10.1007/s002770050203 · Cited by 110
Myeloma : biology and management
Malpas, J. S., Bergsagel, D. E., & Kyle, R. A. (1995) · Cited by 107
Jelinek, D. F., Witzig, T. E., & Arendt, B. K. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.487 · Cited by 105
Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
Avet-Loiseau, H., Daviet, A., Saunier, S., & Bataille on behalf of the Intergrou, R. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02488.x · Cited by 104
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P. F., Gu, W. J., Nilsson, K., Knowles, D. M., II, & Boccadoro, M. (1994) · PubMed · Cited by 103
Familial Multiple Myeloma: a Family Study and Review of the Literature
Lynch, H. T., Sanger, W. G., Pirruccello, S. J., Quinn‐Laquer, B., & Weisenburger, D. D. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1479 · Cited by 103
Rajkumar, S. V., Fonseca, R., Dewald, G. W., et al. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00009-6 · Cited by 101
Shain, K. H., Landowski, T. H., & Dalton, W. S. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00008 · Cited by 99
Development of an in vivo model of human multiple myeloma bone disease
Alsina, M., Boyce, B. F., Devlin, R. D., Anderson, J. L., Craig, F. E., Mundy, G. R., & Roodman, G. D. (1996) · Blood · doi:10.1182/blood.v87.4.1495.bloodjournal8741495 · Cited by 97
Mutations of the p53 gene in human myeloma cell lines.
Mazars, G. R., Portier, M., Zhang, X. G., et al. (1992) · PubMed · Cited by 97
Avet-Loiseau, H., Andree-Ashley, L. E., Moore, D., Mellerin, M. P., Feusner, J., Bataille, R., & Pallavicini, M. G. (1997) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2<124::aid-gcc8>3.0.co;2-0 · Cited by 97
Fonseca, R., Oken, M. M., & Greipp, P. R. (2001) · Blood · doi:10.1182/blood.v98.4.1271 · Cited by 96
Sawyer, J. R., Lukacs, J. L., Thomas, E. L., Swanson, C. M., Goosen, L. S., Sammartino, G., Gilliland, J. C., Munshi, N. C., Tricot, G. J. K., Shaughnessy, J. D., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02546.x · Cited by 95
Billadeau, D. D., Jelinek, D. F., Shah, N., LeBien, T. W., & Ness, B. V. (1995) · PubMed · Cited by 92
Moreau, P., Harousseau, J., Wijdenes, J., Morineau, N., Milpied, N., & Bataille, R. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02093.x · Cited by 88
Interleukin‐1 in multiple myeloma: producer cells and their role in the control of IL‐6 production
Costes, V., Portier, M., Lu, Z., Rossi, J., Bataille, R., & Klein, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01101.x · Cited by 87
FLACTIF, M., Zandecki, M., Laï, J. L., et al. (1995) · PubMed · Cited by 83
Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility
Zhang, S.-L., DuBois, W., Ramsay, E. S., Bliskovski, V., Morse, H. C., Taddesse-Heath, L., Vass, W. C., DePinho, R. A., & Mock, B. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.1.310-318.2001 · Cited by 82
Lacy, M. Q., Donovan, K. A., Heimbach, J. K., Ahmann, G. J., & Lust, J. A. (1999) · Blood · doi:10.1182/blood.v93.1.300 · Cited by 81
Bertolini, F., Mancuso, P., Gobbi, A., & Pruneri, G. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00508-7 · Cited by 79
Guillerm, G., Gyan, E., Wołowiec, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.244 · Cited by 78
Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó, K., Silva, S., Pálóczi, K., Domján, G., & Falus, A. (2001) · PubMed · Cited by 75
Asosingh, K., Günthert, U., Bakkus, M. H. C., Raeve, H. D., Goes, E., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2000) · PubMed · doi:10.5451/unibas-ep6481 · Cited by 74
Myeloma: Biology and Management
Jackson, G. H. (2004) · Clinical Oncology · doi:10.1016/j.clon.2004.06.004 · Cited by 71
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance
Königsberg, R., Ackermann, J., Kaufmann, H., Zojer, N., Urbauer, E., Krömer, E., Jaeger, U., Gisslinger, H., Schreiber, S. C., Heinz, R., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401909 · Cited by 70
Kyle, R. A., Beard, C. M., O'Fallon, W. M., & Kurland, L. T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1577 · Cited by 67
H�nemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., D�rken, B., & Bargou, R. C. (2001) · International Journal of Cancer · doi:10.1002/ijc.1388 · Cited by 65
Chromosomal abnormalities in systemic amyloidosis
Fonseca, R., Ahmann, G. J., Jalal, S. M., Dewald, G. W., Larson, D. R., Therneau, T. M., Gertz, M. A., Kyle, R. A., & Greipp, P. R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01034.x · Cited by 63
P53 deletion is not a frequent event in multiple myeloma
Avet‐Loiseau, H., Li, J., Godon, C., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01615.x · Cited by 63
Tsunenari, T., Koishihara, Y., Nakamura, A., Moriya, M., Ohkawa, H., Goto, H., Shimazaki, C., Nakagawa, M., Ohsugi, Y., Kishimoto, T., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2437 · Cited by 63
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Rebouissou, C., Wijdenes, J., Autissier, P., Tarte, K., Costes, V., Liautard, J., Rossi, J.-F., Brochier, J., & Klein, B. (1998) · Blood · doi:10.1182/blood.v91.12.4727 · Cited by 63
Zandecki, M., Laï, J., Geneviève, F., Bernardi, F., Volle-Rémy, H., Blanchet, O., François, M., Cosson, A., Bauters, F., & Facon, T. T. F. (1997) · Blood · doi:10.1182/blood.v90.9.3682 · Cited by 61
Gutierrez, N. C., Hernández, J., García, J., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402116 · Cited by 59
Expression of p16INK4A and p14ARF in hematological malignancies
Taniguchi, T., Chikatsu, N., Takahashi, S., Fujita, A., Uchimaru, K., Asano, S., Fujita, T., & Motokura, T. (1999) · Leukemia · doi:10.1038/sj.leu.2401557 · Cited by 57
Billadeau, D. D., Liu, P., Jelinek, D. F., Shah, N., LeBien, T. W., & Ness, B. G. V. (1997) · PubMed · Cited by 55
Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo
Ge, N.-L., & Rudikoff, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203801 · Cited by 55
Asosingh, K., Günthert, U., Raeve, H. D., et al. (2001) · PubMed · doi:10.5451/unibas-ep6480 · Cited by 54
The Role of Adhesion Molecules in Multiple Myeloma
Cook, G., Dumbar, M., & Franklin, I. M. (2009) · Acta Haematologica · doi:10.1159/000203663 · Cited by 53
Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia
Uchida, T., Kinoshita, T., Ohno, T., Ohashi, H., Nagai, H., & Saito, H. (2001) · Leukemia · doi:10.1038/sj.leu.2401991 · Cited by 48
Immune regulation in multiple myeloma: the host–tumour conflict
Cook, G., & Campbell, J. D. M. (1999) · Blood Reviews · doi:10.1054/blre.1999.0111 · Cited by 46
Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy
Sezer, O., Niemöller, K., KAUFMANN, O. W., Eucker, J., Jakob, C., Zavrski, I., & Possinger, K. (2001) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2001.066004238.x · Cited by 44
Andreasson, P., Johansson, B., Arheden, K., Billström, R., Mitelman, F., & Höglund, M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2<77::aid-gcc2>3.0.co;2-x · Cited by 42
Dalton, W. S., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C., & Harousseau, J. L. (2001) · Hematology · doi:10.1182/asheducation-2001.1.157 · Cited by 36
Self-citationCharacterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
Urashima, M., Teoh, G., Ogata, A., et al. (1997) · PubMed · Cited by 35
The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases
Zandecki, M., Facon, T. T. F., Preudhomme, C., et al. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509059651 · Cited by 35
EXPERIMENTAL PLASMACYTOMAGENESIS IN MICE
Potter, M. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70434-2 · Cited by 32
Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma
Aalto, Y., Nordling, S., Kivioja, A., Karaharju, E. O., Elomaa, I., & Knuutila, S. (1999) · Genes Chromosomes and Cancer · Cited by 32
The Retinoblastoma Susceptibility Gene RB-1 in Multiple Myeloma
Juge‐Morineau, N., Harousseau, J., Amiot, M., & Bataille, R. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709039011 · Cited by 31
Radl, J., Punt, Y., van den Enden-Vieveen, M. H. M., et al. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.51 · Cited by 27
Homing mechanisms of myeloma cells.
Riet, I. V. (1999) · PubMed · Cited by 27
Multiple myeloma and related disorders. Lessons from an animal model.
Radl, J. (1999) · PubMed · Cited by 24
Worel, N., Greinix, H., Ackermann, J., Kaufmann, H., Urbauer, E., cker, P. H. X. F., Gisslinger, H., Lechner, K., Kalhs, P., & Drach, J. W. (2001) · Annals of Hematology · doi:10.1007/s002770100296 · Cited by 23
Zhu, Z., ARKEL, V., KING, et al. (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00428.x · Cited by 22
Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases.
Skopelitou, A. S., Hadjiyannakis, M., Tsenga, A., Theocharis, S. E., Alexopoulou, V., Kittas, C., & Agnantis, N. (1993) · PubMed · Cited by 21
Cytogenetic findings in mouse multiple myeloma and Waldenström's macroglobulinemia
van den Akker, T. W., Radl, J., Franken‐Postma, E. M., et al. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00169-7 · Cited by 20
Red swollen nail folds and nail deformity as presenting findings in chronic lymphocytic leukaemia
Yağcı, M., Sucak, G. T., & Haznedar, R. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02650.x · Cited by 18
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma
Urashima, M., Teoh, G. K. H., Ogata, A., Chauhan, D., Treon, S. P., Hoshi, Y., DeCaprio, J. A., & Anderson, K. C. (1997) · Leukemia · doi:10.1038/sj.leu.2400843 · Cited by 17
Update of gp130 cytokines in multiple myeloma
Klein, B. (1998) · Current Opinion in Hematology · doi:10.1097/00062752-199805000-00007 · Cited by 16
Ollikainen, H., Syrjänen, S., Koskela, K., et al. (1997) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519709099401 · Cited by 12
Genetics of chronic lymphocytic leukaemia
Kipps, T. J. (2000) · Hematology and Cell Therapy · doi:10.1007/s00282-000-0005-4 · Cited by 11
Pope, B., Brown, R. D., Luo, X.-F., et al. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709039043 · Cited by 9
Stacey, M. W., Wang, J., Byrd, R. L., Liu, J. M., & Kearns, W. G. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199906)25:2<115::aid-gcc7>3.0.co;2-2 · Cited by 7
Research works printed but not linked: 6
- Jernberg-Wiklund, H. & Nilsson, K. in Human Cell Culture Vol. 3 (eds Masters, J. R. W. & Palsson, B. O.) 81–155 (Kluwer Academic, The Netherlands, 2000).
- Avet-Loiseau, H. in VIIIth International Myeloma Workshop 10–11 (Banff, Alberta, Canada, 2001).
- Epstein, J., Yaccoby, S. & Fujii, R. in VIIIth International Myeloma Workshop 21–22 (Banff, Alberta, Canada, 2001).
- Fonseca, R. et al. A molecular classification of multiple myeloma (MM), based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis. Blood 98, A733 (2001). · DOI · Paper page
- Stinchcombe, T. E. et al. PS-341 is active in multiple myeloma: preliminary reports of a Phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 98, A516 (2000).
- Bergsagel, P. L. & Kuehl, W. M. in Myeloma: Biology and Management (eds Malpas, J. S., Bergsagel, D. E., Kyle, R. & Anderson, K. C.) (Oxford Univ. Press, Oxford, 1998).
Cited by
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
“Anomalously, this was not the case for MMs, a malignancy of antibody-producing plasma cells (reviewed in Kuehl and Bergsagel, 2002 ), in which the DEPTOR mRNA is overexpressed (Figure 6A, Table S1).”
BackgroundSelf-citationThe molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Metadata
- Authors
- Kuehl, W. M., & Bergsagel, P. L.
- Affiliations
- National Institutes of Health (US)
- Cornell University (US)
- ORCID
- Bergsagel, P. Leif
- Venue
- Nature Reviews Cancer
- Published
- 2002-03
- Volume
- 2
- Issue
- 3
- Pages
- 175-187
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984534203
- Cited by
- 818
- References
- 164
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 16 · 2023: 30 · 2022: 17 · 2021: 15 · 2020: 26 · 2019: 27 · 2018: 24 · 2017: 32 · 2016: 34 · 2015: 37 · 2014: 34 · 2013: 43 · 2012: 38
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, plasma cells, chromosomal translocation, immunoglobulin enhancer, oncogenes, chromosomal abnormalities, host-pathogen interaction, cancer prevention, myeloma treatment, B cell differentiation
- MeSH terms
- B-Lymphocytes, Enhancer Elements, Genetic, Humans, Immunoglobulins, Multiple Myeloma, Neoplasm Staging, Oncogenes, Translocation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.